A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Incremental Study for the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Healthy Volunteers.
Latest Information Update: 01 Dec 2020
At a glance
- Drugs QX 005N (Primary)
- Indications Allergic rhinitis; Asthma; Atopic dermatitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 01 Dec 2020 New trial record